Chronic lymphocytic leukemia treatment

Venetoclax is an effective treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), either alone or in combination with other drugs like rituximab or obinutuzumab.
Key points about venetoclax in CLL treatment:

It is the first selective, orally bioavailable BCL-2 inhibitor that has received FDA approval.
Venetoclax provides good therapeutic responses in CLL patients irrespective of adverse clinical or genetic features, including in relapsed/refractory CLL.
Fixed-duration venetoclax-based regimens like VEN+G and VEN+R can achieve durable progression-free survival (PFS) without continuous treatment.
In the CLL14 trial, the VEN+G regimen demonstrated improved PFS compared to chlorambucil plus obinutuzumab in previously untreated CLL.
The MURANO trial showed the VEN+R regimen improved PFS versus bendamustine plus rituximab in relapsed/refractory CLL.